New hope for kidney transplant patients: extended drug trial targets rejection

NCT ID NCT07444489

ENROLLING_BY_INVITATION Disease control Sponsor: Biogen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study offers kidney transplant patients with antibody-mediated rejection (AMR) the chance to receive felzartamab for up to 4 more years. AMR occurs when the immune system attacks the new kidney. The main goal is to check long-term safety and monitor kidney health through biopsies and lab tests. Participants who already received felzartamab in a prior study can join, while those who stopped the drug will only be monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIBODY MEDIATED REJECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute transplant rejection endotheliitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIBODY MEDIATED REJECTION MICROVASCULAR INFLAMMATION

Contacts and locations

Locations

California Pacific Medical Center (Sutter Health)

San Francisco, California, 94115, United States
Cooperman Barnabas Medical Center

West Orange, New Jersey, 07039, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Penn Medicine - Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
The Ohio State University

Columbus, Ohio, 43210, United States
UCLA College of Medicine

Los Angeles, California, 90095, United States
University of Nebraska Medical Center (UNMC) - Nebraska Medicine - Nebraska Medical Center

Omaha, Nebraska, 68198-3040, United States
University of Washington Medical Center

Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.